Genentech has initiated a phase 3 trial to evaluate the Port Delivery System with ranibizumab to treat diabetic retinopathy in patients without diabetic macular edema, according to company correspondence.
The multicenter, randomized Pavilion trial is expected to enroll 160 patients to receive either the study drug, Port Delivery System implant prefilled with ranibizumab (PDS), or intravitreal ranibizumab injections.
Patients in the study arm will receive refills at intervals of 9 months. At 16 months, patients in the comparator arm will be eligible to receive the PDS.
Pavilion’s primary
Uncategorized